NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.

  title={NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.},
  author={Derk Pol and Claire Curtis and Satish Ramkumar and Logan Bittinger},
  journal={Heart, lung \& circulation},
  volume={28 4},
Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review
The review found that switching among OACs was common in clinical practice, significantly varying with the type of OAC, and did not have a significant impact on the risk of stroke and other thrombotic outcomes.
Analysis of Influencing Factors of Compliance with Non-Vitamin K Antagonist Oral Anticoagulant in Patients with Nonvalvular Atrial Fibrillation and Correlation with the Severity of Ischemic Stroke
Clinical supervision and management of patients with NVAF after NOACs should be strengthened to improve the compliance of patients in China, reduce the damage of ischemic stroke, and improve their prognosis.
Changing paradigms: from prevention of thromboembolic events to improved survival in patients with atrial fibrillation.
  • C. Escobar, A. Camm
  • Medicine
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2020
A novel risk stratification approach based on the mortality associated with stroke and bleeding is proposed, illustrated by data derived from the literature.
Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
Differences according to the clinical setting of each study were found, atrial fibrillation patients taking rivaroxaban in Spain were elderly and had a high thromboembolic risk.
Supporting anticoagulant treatment decision making to optimise stroke prevention in complex patients with atrial fibrillation: a cluster randomised trial
Specialist feed-back in addition to an educational session did not increase the uptake of anticoagulation in patients with AF, and antithrombotic treatment as appropriate against guideline recommendations was not assessed.
Evaluating equality in prescribing Novel Oral Anticoagulants (NOACs) in England: The protocol of a Bayesian small area analysis
A new statistical modelling approach to link prescription and socioeconomic data to model pharmacoepidemiologic data will help develop geographically targeted public health interventions, campaigns, audits, or guidelines to improve areas of low prescription.
Ischaemic stroke and transient ischaemic attack on anticoagulants: outcomes in the era of direct oral anticoagulants
A retrospective review of patients who presented to a high‐volume primary stroke centre with acute stroke symptoms while prescribed an oral anticoagulant between January 2012 and June 2017 found thatAnticoagulated patients diagnosed with stroke or transient ischaemic attack shared similar disease and outcome characteristics irrespective of antICOagulants used.


Apixaban versus warfarin in patients with atrial fibrillation.
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Dabigatran versus warfarin in patients with atrial fibrillation.
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.